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Abstract  
The pattern of epidemic meningococcal disease in the African meningitis belt may be 
influenced by the background level of population immunity but this has been measured 
infrequently. A standardised enzyme-linked immunosorbent assay (ELISA) for measuring 
meningococcal serogroup A IgG antibodies was established at five centres within the 
meningitis belt.  Antibody concentrations were then measured in 3930 individuals stratified 
by age and residence from six countries. Seroprevalence by age was used in a catalytic 
model to determine the force of infection. Meningococcal serogroup A IgG antibody 
concentrations were high in each country but showed heterogeneity across the meningitis 
belt. The geometric mean concentration (GMC) was highest in Ghana (9.09 µg/mL [95% CI 
8.29, 9.97]) and lowest in Ethiopia (1.43 µg/mL [95% CI 1.31, 1.57]) on the margins of the 
belt. The force of infection was lowest in Ethiopia (λ = 0.028). Variables associated with a 
concentration above the putative protective level of 2 µg/mL were age, urban residence and 
a history of recent vaccination with a meningococcal vaccine. Prior to vaccination with the 
serogroup A meningococcal conjugate vaccine, meningococcal serogroup A IgG antibody 
concentrations were high across the African meningitis belt and yet the region remained 
susceptible to epidemics.   
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Introduction 
Epidemics of meningococcal disease have occurred at irregular intervals across the Sahelian 
and sub-Sahelian regions of Africa, the African meningitis belt, for over 100 years.[1] 
However, despite many years of research it is still not known why epidemics occur at a 
particular place at any specific time.  An important factor is likely to be the background level 
of immunity of the population when faced with a potentially epidemic strain. It is known 
that protective immunity to Neisseria meningitidis can be induced by meningococcal 
carriage,[2] infection with other non-pathogenic Neisseria species, such as N. 
lactamica[3]and possibly by other bacteria.[4,5]  There is also some evidence that 
background immunity may be impaired with infection by other bacteria that induce blocking 
antibodies.[6] The immune response to meningococcal polysaccharide and conjugate 
vaccines has been studied  in the African meningitis belt[7-10] on several occasions  but 
there have been few studies of population levels of antibody to N. meningitidis in the 
African meningitis belt.[11,12] Therefore, we have undertaken a study of community levels 
of serogroup-specific IgG antibody to N. meningitidis serogroup A (NmA) in six countries in 
the African meningitis belt before the introduction of the serogroup A conjugate vaccine, 
MenAfriVac™, to investigate heterogeneity in the level of exposure across the meningitis 
belt and to use age specific antibody titres to measure the force of infection.[13] To ensure 
that patterns of antibody could be compared across sites, we implemented standardised 
methods supported by careful quality control.         
Materials and methods 
Study population 
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Cross-sectional meningococcal carriage surveys were conducted in seven countries across 
the meningitis belt during the period July 1st 2010 to July 31st 2012 as described 
previously.[14] Ethical approval for the study was obtained from the London School of 
Hygiene & Tropical Medicine and from an appropriate committee from each African centre. 
Written, informed consent for study participation was obtained from adults and for the 
children under their care. Written informed assent was also obtained from participants aged 
12 years or more. Oral assent was obtained from younger children.    
Subjects were selected randomly from within populations which were part of a routine 
demographic survey system (DHSS) or in which a census had been performed recently.  The 
study population was recruited from urban and rural populations and stratified into four age 
groups:  < 5 years, 5-14 years, 15-29 years and 30 years or older.  
Subjects were asked if they had received a meningitis vaccine in the previous six months. 
Approximately a year before the survey, a vaccination campaign with an A + C 
polysaccharide vaccine had been conducted in the study area in Senegal and also in part of 
the urban study area in Niger.[15] None of the study populations had been vaccinated with 
MenAfriVac™ at the time of the survey.  
Blood samples were collected from the first 100 subjects surveyed within each of the four 
age bands in both urban and rural study sites, giving an overall target of 800 samples per 
country.  This target was achieved, or nearly achieved, except in Senegal where there was 
some resistance to the collection of blood samples. A 5 mL sample was collected, serum 
separated within six hours of collection and then stored at -20°C until assayed.  
Enzyme Linked Immuno-Sorbent Antibody (ELISA) assay  
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An internationally standardised ELISA, as used at the Vaccine Evaluation Unit (VEU), Public 
Health England, Manchester, UK was transferred to each of the MenAfriCar centres. 
Concentrations of IgG antibody against N. meningitidis serogroup A polysaccharide  were 
obtained through a classical sandwich assay ELISA as  described previously,[16]  except that 
the standard reference serum CDC1992 was used as the quantification reference and that a 
monoclonal-PAN anti-human IgG Fc labelled with horseradish peroxidase (HRP)(Hybridoma 
Reagent Laboratory, Baltimore, MD) was used as  conjugate. The lower limit of 
quantification (LLQ) of the meningococcal serogroup A ELISA was 0.19 µg/mL. Any value 
lower than the LLQ was assigned a value of 0.095 µg/mL for computational purposes.  
 
Standardisation of the assay and quality control 
To ensure comparability of assay methods between centres, two training sessions were held 
in Manchester, UK and in Bamako, Mali at the start of the project.  Subsequently, 
approximately 50 samples obtained during a pilot study conducted in each country were 
selected to allow cross-validation of the technique between each of the centres and the 
VEU, Manchester. After repeated testing of the 50 samples and adjustment of the technique 
to ensure that the results obtained fell within a defined range of the results obtained at the 
VEU, authorization was given to start testing the samples obtained during the cross-
sectional survey. During the course of testing, monitoring of key values was performed by a 
resident scientist: two values representative of the standard curves (average of the 
duplicate values of the second higher concentration point and midpoint of the slope) as well 
as the calculated concentration of the local positive control were plotted routinely on Levey-
Jennings charts. Regular review of these data was undertaken by the MenAfriCar laboratory 
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manager and advice provided on adjustment of the technique when problems arose, for 
example detection of degradation in the anti-IgG conjugate used in the assay.  It was not 
possible to complete cross-validation in Nigeria due to increasing insecurity and samples 
collected in Nigeria were tested in Mali. The laboratory in Chad did not reach the required 
standard in the validation assay to progress to testing of cross-sectional samples.    
Statistical methods 
Pearson’s correlation coefficient () was used to compare the results produced at the VEU 
and by each centre during the validation exercise. The acceptance criterion for passing the 
cross-validation test was greater than or equal to 0.9. In addition, Lin’s concordance 
coefficient of correlation, (C), which evaluates the degree to which pairs of observations 
fall on the 45° line through the origin and which provides a measure of both precision and 
accuracy of an assay was used.[17]  
For analysis of the results from samples obtained during the cross-sectional surveys, 
geometric mean antibody concentrations (GMCs) were calculated and the percentage of 
samples reaching the putative protective threshold of ≥2 µg/mL,[18] together with 95% 
confidence intervals, was determined.  Results by country were analysed graphically using 
reverse cumulative distribution plots. GMCs were compared by urban /rural residence and 
by sex in each country using a t-test. Risk factors for seropositivity (i.e. antibody 
concentration ≥2 µg/mL) were investigated using logistic regression. A multivariable logistic 
regression model was developed as follows: all variables with a p-value <0.1 in univariable 
analyses were included initially, then any variable with p-value <0.05 in the multivariable 
model was retained, with excluded variables re-entered one by one. If any of the re-entered 
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variables had a p-value <0.05, they were retained in the final model.  Because the survey 
was designed with the household as the primary sampling unit, and to account for potential 
household clustering, we used the survey commands in Stata (StataCorp, Texas). 
Seroprevalence was stratified into yearly age groups and then analysed using a reverse 
catalytic modelling approach under a binomial sampling assumption, as described 
elsewhere.[13] Two key parameters were estimated using this approach (1) the 
seroconversion rate (SCR), i.e. the annual rate at which individuals change from 
seronegative to seropositive, also known as the force of infection (λ) and (2) the 
seroreversion rate, the annual rate at which seropositive individuals revert to a seronegative 
state (SRR or r). The catalytic model was fitted using a maximum likelihood approach. 
Analyses were repeated, excluding individuals who reported recent vaccination to estimate 
‘natural’ immunity. 
All analyses were performed using Stata v12.0.  
Ethics 
The purpose and methods of the study were explained to community leaders at community 
meetings and through the media. Written, informed consent for obtaining a pharyngeal 
swab and a blood sample was obtained from adults and for the children under their care. 
Written informed assent was also obtained from participants aged 12 years or more. Oral 
assent was obtained from younger children.   Consent and assent forms were translated into 
the relevant local language.   
The study protocols, consent and assent forms were approved by the LSHTM Ethics 
Committee and by the ethics committees of each of the African partner institutions with the 
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exception of Chad, which does not have a formal ethical committee, and where approval for 
the activities of the consortium was granted by a committee set up to oversee MenAfriCar 
studies by the Ministry of Health.   
Results 
Cross-validation  
Although the cross-validation exercise required several rounds of testing, five centres finally 
achieved excellent results with Pearson correlation values (ρ) between 0.926 and 0.996         
(Table 1). Final results obtained in Ghana are shown as an example in S1 Fig. Following the 
validation exercise, quality control of the results obtained on analysis of the cross-sectional 
survey samples was ensured by monitoring the key parameters of the standard curve as well 
as the local positive controls, as shown for Ethiopia in Figure A in S2 Fig.  
Meningococcal serogroup A IgG antibodies by country and by sub-group  
 Sera obtained from 3930 individuals in six African meningitis belt countries were tested. 
The prevalence of serogroup A specific IgG antibodies for each country is shown as a reverse 
cumulative plot in Fig 1. There were significant differences GMC by country with Ghana 
having the highest mean GMC and Ethiopia the lowest (Table 2). 
The GMC increased with age in all countries with the exception of Senegal where there was 
a drop in GMC in those over 30 years of age (Table 3). This was less apparent when subjects 
with a history of recent vaccination were excluded. In four countries, no differences in 
GMCs by sex were observed (Ethiopia, Niger, Nigeria, Senegal, p>0.2 in each country); in 
Ghana and Senegal GMCs were higher in females compared to males (p=0.0002 and 
p=0.0203, respectively). A comparison was made in each country between GMCs according 
to whether the study site was urban or rural and by the sex of the participant. In five 
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countries, NmA-specific IgG GMCs were higher in urban than in rural areas (p<0.0001 for 
Ethiopia, Ghana, Mali and Niger, p=0.0012 for Senegal); in Nigeria, GMC was higher in the 
rural study site (p=0.0123).  
Factors associated with NmA-specific IgG concentrations above the putative protective 
threshold of 2µg/ml are shown in Table 4. The multivariable model included the following 
factors shown to be associated with a higher odds of seropositivity in addition to observed 
country-level differences: urban location, increasing age and reported receipt of a 
meningitis vaccine which is likely to have contained the serogroup A polysaccharide. Current 
carriage of meningococci or other Neisseria species were not associated with seropositivity 
in the multivariable model. 
The influence of age on the putative protective threshold of 2 µg/mL is further shown by 
country in Figs 2 and 3.  
Force of infection 
The force of infection was calculated based on the age prevalence of seropositivity as 
described above. Unexpectedly, this was highest in Senegal, even when subjects with a 
recent history of vaccination were excluded, followed by Ghana and Niger; Ethiopia had the 
slowest seroconversion rate (Table 5). 
Discussion 
Although a number of studies of meningococcal serology have been performed previously in 
countries of the African meningitis belt, most of these have been undertaken in the context 
of evaluation of the response to vaccination[7-10] or in disease survivors.[19] Comparisons 
between the results obtained in individual studies can be difficult when standardised 
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methods are not used. Therefore, for this comparative study, substantial efforts were made 
to standardise the ELISA technique used at each of the collaborating centres with support 
from the Vaccine Evaluation Unit at PHE, Manchester, UK. This proved more challenging 
than anticipated and satisfactory results were not obtained at one out of six centres prior to 
the end of the project.  Problems encountered included the short shelf-life of some of the 
reagents required, difficulties in clearing reagents through customs and difficulties in 
shipping frozen samples to the UK for validation.  However, despite these challenges, 
excellent results were eventually obtained at five centres using Pearson coefficient of 
correlation (r>0.92) and satisfactory ones using Lin’s concordance coefficient of correlation, 
allowing adjustment of some issues which were not identified using the correlation 
coefficient alone.  
Overall, serogroup A meningococcal IgG antibody concentrations were high in the African 
populations investigated, with the highest GMCs being obtained in countries in the centre of 
the meningitis belt. This has been noted previously.[10,11] This was the case despite the 
fact that there was little circulation of the serogroup A meningococcus in the African 
meningitis belt at the time of the study.[20] These high antibody concentrations probably 
reflect prior exposure to the serogroup A meningococcus and  other cross-reactive bacteria 
such as Bacillus pumilis [5,21] and Escherichia coli capsule types K51 or K93.[22] Similarly 
high serogroup A meningococcal IgG antibody concentrations have been found In 
industrialised countries where there is no group A disease and no evidence of carriage.  For 
example, in England and Wales a GMC of 4.75 µg/mL was found in the general population 
with 87% of individuals with antibody levels ≥2 µg/mL,[23] an observation which supports 
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the role for cross-reactive bacteria in inducing antibodies against the serogroup A 
meningococcus. 
 None of the populations in the MenAfriCar cross-sectional surveys had been vaccinated 
previously with MenAfriVac™ but meningococcal vaccines containing A polysaccharide have 
been used quite extensively in some of the study countries in the past. Subjects were asked 
whether they had received a meningitis vaccine in the previous six months and if this was 
the case, they are likely to have been vaccinated with a vaccine containing serogroup A 
polysaccharide. Analyses of antibody distribution by country and by age were undertaken 
excluding these subjects but this had little impact on the pattern of results. However, earlier 
vaccination campaigns may have resulted in some persistent antibody. Prior vaccination 
may be the reason for the rapid seroconversion rate in the Senegalese population where a 
mass vaccination campaign with an A + C polysaccharide vaccine had been undertaken in 
2010, about 12 months prior to the study and also for the reason why the GMC was lower in 
subjects over 30 years of age in Senegal than in younger subjects who would not have been 
targeted in the immunisation campaign.   Thus, the antibody distribution seen in each 
country may reflect a combination of responses induced by both natural exposure and 
vaccination.  
An Ig meningococcal serogroup A polysaccharide antibody concentration of > 2 µg/mL as 
measured by radioimmunoassay has been suggested as a correlate of protection against 
serogroup A  meningococcal disease based on the results of a trial of a meningococcal 
polysaccharide vaccine conducted in Finland in the 1970s.[18] However, it seems unlikely 
that this is the case in countries of the meningitis belt where a high proportion of the 
population has antibody concentrations above this value and yet, until the introduction of 
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MenAfriVac™, the region remained peculiarly susceptible to large serogroup A epidemics. It 
is likely that much of the antibody detected by ELISA is non-functional, perhaps because it is 
induced by cross-reacting bacteria.  Bactericidal antibodies are the accepted correlate of 
protection for meningococcal disease [24] and measurement of serogroup A serum 
bactericidal antibodies may give a better reflection of the background level of immunity of a 
community. However, these are technically more difficult to perform reliably than the ELISA, 
and were only undertaken at two of the centres that participated in this study before and 
after the introduction of MenAfriVac™. These results, together with studies of the correlates 
of protection against invasive meningococcal disease and meningococcal pharyngeal 
carriage will be reported subsequently. 
In this study, we have shown that serology can be used to show differences in exposure to 
meningococcal infection between countries and age groups and we have shown how age 
dependent variations in seropositivity can be used to measure the force of infection. The 
force of infection was generally highest in countries in the centre of the meningitis belt, with 
the exception of Senegal where the situation may have been confounded by vaccination, 
and   lowest in Ethiopia on the margin of the belt.  Measurement of seroconversion by age 
has proved to be a valuable approach to study of the epidemiology of malaria and of the 
impact of control interventions on this infection [25,26] and, as shown here, is valuable for 
the study of other infectious diseases. Further study of antibody kinetics in the African 
meningitis belt is important for understanding the epidemiology of meningococcal infection 
and monitoring control measures including widespread deployment of conjugate vaccines.  
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FIGURE LEGENDS 
Fig 1:  Reverse cumulative distribution curves of meningococcal serogroup A IgG antibodies 
by country. 
Fig 2:  Statistical analysis of seropositivity data for all individuals. Age-adjusted 
seroprevalence (blue solid lines) using appropriate reversible catalytic models. The observed 
seroprevalences (red-filled triangles) were pooled according to the 10%-centiles of the 
underlying age distribution.   
Fig 3:  Statistical analysis of seropositivity data excluding vaccinated individuals. Age-
adjusted seroprevalence (blue solid lines) using appropriate reversible catalytic models. The 
observed seroprevalences (red-filled triangles) were pooled according to the 10%-centiles of 
the underlying age distribution.   
 
SUPPLEMENTARY FILES 
S1 Fig 
S2 Fig 
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TABLES 
Table1: Statistical analysis of a comparison of meningococcal serogroup A IgG 
concentrations obtained at the Vaccine Evaluation Unit (VEU), Public Health England and 
at five MenAfriCar centres. 
Variable/ Country Ethiopia Ghana Mali 1 Mali 2
* 
Niger Senegal 
Number of sera tested 50 (29 + 21) 49 50 29 50 60 (39 + 21) 
Range of values tested 
(ug/ml) 
0.095 – 
133.38 
0.34 – 133.38 0.43 – 67.42 0.095 – 
3.42 
0.095 – 
79.36 
0.28 – 
133.38 
Pearson’s correlation 
coefficient  (ρ) 
0.996 0.994 0.859 0.947 0.938 0.996 
Lin’s concordance 
coefficient (ρc) 
0.988 0.991 0.858 0.825 0.757 0.966 
Slope 1.135 0.930 0.970 1.338 0.577 1.281 
Intercept -0.957 -0.372 0.010 0.159 0.966 -0.703 
 
Footnote: * Two sets of validation samples were used for Mali because the correlation co-
efficient from the first 50 samples did not reach the required threshold of 0.9. The second 
set of samples was selected from a set tested at the VEU which gave consistent results when 
tested in Manchester, UK. 
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Table 2: Geometric mean meningococcal serogroup A IgG antibody concentrations and 
seroprevalence by country.   
A. All individuals 
Country Number GMC (95% CI) % ≥2ug/ml (95% CI) 
Ethiopia 619 1.43 (1.31, 1.57) 33.8% (30.0, 37.5%) 
Ghana 765 9.09 (8.29, 9.97) 87.6% (85.2, 89.9%) 
Mali 756 2.04 (1.77, 2.34) 52.1% (48.5, 55.7%) 
Niger 826 4.98 (4.37, 5.66) 65.6% (62.3, 68.8%) 
Nigeria 584 2.24 (1.91, 2.62) 52.1% (48.1, 56.2%) 
Senegal 380 5.90 (5.00, 6.96) 81.1% (77.1, 85.0%) 
 
B. Excluding individuals with a history of recent meningococcal vaccination 
Country Number GMC (95% CI) % ≥2ug/ml (95% CI) 
Ethiopia 617 1.43 (1.31, 1.57) 33.7% (30.0, 37.4%) 
Ghana 650 8.70 (7.89, 9.59) 87.2% (84.6, 89.8%) 
Mali 706 2.10 (1.82, 2.43) 52.7% (49.0, 56.4%) 
Niger 757 5.24 (4.59, 5.99) 66.8% (63.5, 70.2%) 
Nigeria 559 2.20 (1.88, 2.58) 52.0% (47.9, 56.2%) 
Senegal 178 3.96 (3.05, 5.15) 74.7% (68.3, 81.1%) 
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Table 3. Geometric mean meningococcal serogroup A IgG antibody concentrations (95% CI) 
by age and country. 
A. All individuals 
Country Age group (years) 
 < 5 5-14 15-29 >=30  
Ethiopia 0.62 (0.53, 0.72) 0.89 (0.78, 1.03) 1.86 (1.59, 2.17) 2.68 (2.30, 3.14) 
Ghana 2.48 (1.92, 3.19) 6.25 (5.06, 7.72) 11.59 (9.97, 13.47) 12.06 (10.55, 
13.80) 
Mali 0.28 (0.13, 0.34) 1.89 (1.46, 2.46) 5.75 (4.67, 7.08) 5.86 (4.84, 7.10) 
Niger 0.89 (0.72, 1.10) 3.39 (2.67, 4.31) 10.99 (8.90, 13.57) 14.36 (11.89, 
17.35) 
Nigeria 0.39 (0.30, 0.51) 1.00 (0.78, 1.29) 5.07 (3.95, 6.50) 8.88 (7.25, 10.88) 
Senegal 1.84 (1.18, 2.87) 7.40 (5.46, 10.02) 11.95 (9.01, 15.87) 5.48 4.26, 7.07) 
 
B. Excluding individuals with a history of recent meningococcal vaccination 
Country Age group (years) 
 < 5 5-14 15-29 >=30  
Ethiopia 0.62 (0.53, 0.72) 0.89 (0.78, 1.03) 1.86 (1.59, 2.17) 2.68 (2.30, 3.14) 
Ghana 2.41 (1.81, 3.22) 5.79 (4.64, 7.23) 11.36 (9.65, 13.38) 11.29 (9.81, 13.00) 
Mali 0.26 (0.22, 0.32) 1.92 (1.46, 2.53) 5.67 (4.59, 7.00) 6.04 (4.98, 7.33) 
Niger 0.94 (0.75, 1.19) 3.50 (2.72, 4.50) 10.89 (8.73, 13.57) 14.26 (11.77, 
17.28) 
Nigeria 0.39 (0.30, 0.51) 0.89 (0.70, 1.14) 4.88 (3.81, 6.26) 8.59 (7.02, 10.52) 
Senegal 0.94 (0.41, 2.19) 3.68 (1.41, 9.60) 6.21 (3.28, 11.78) 5.10 (3.86, 6.74) 
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Table 4: Logistic regression analysis of factors associated with a meningococcal serogroup A 
IgG concentration ≥2ug/ml, a putative correlate of protection. 
Variable N Crude Odds Ratio 
(95% CI) 
Adjusted Odds Ratio 
(95% CI) 
Country    
Ethiopia 619 0.27 (0.21, 0.33) 0.15 (0.11, 0.20) 
Ghana 765 3.72 (2.83, 4.91) 2.79 (2.03, 3.85) 
Mali 756 0.57 (0.46, 0.71) 0.49 (0.38, 0.64) 
Niger (baseline) 826 1.0 1.0 
Nigeria 583 0.57 (0.46, 0.71) 0.44 (0.34, 0.58) 
Senegal 380 2.24 (1.65, 3.00) 2.02 (1.31, 3.12) 
    
Age group    
0 to 4 years 746 0.09 (0.07, 0.11) 0.06 (0.05, 0.08) 
5 to 14 years 957 0.32 (0.27, 0.39) 0.26 (0.21, 0.32) 
15 to 29 years (baseline) 1023 1.0 1.0 
30+ years 1203 1.59 (1.29, 1.96) 1.68 (1.33, 2.12) 
    
Sex    
Female  2241 1.0 Not included 
Male 1668 0.82 (0.72, 0.93)  
Not known 20   
    
Urban 1871 1.0 1.0 
Rural 2058 0.64 (0.56, 0.73) 0.54 (0.45, 0.64) 
    
Recently vaccinated with a 
meningitis vaccine 
   
No 3459 1.0 1.0 
Yes 463 2.09 (1.65, 2.66) 1.71 (1.23, 2.38) 
    
Meningococcal carrier    
No 3771 1.0 Not included 
Yes 158 0.94 (0.67, 1.31)  
    
Carrier of other Neisseria species    
No 3706 1.0 Not included 
Yes 224 0.40 (0.30, 0.53)  
    
Crowded living conditions*    
No 1438 1.0 Not included 
Yes 2484 0.70 (0.60, 0.81)  
24 
 
* crowding was defined as >=2 people per room as used previously28 
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Table 5 : Estimates of the annual force of infection (λ) and seroreversion (r) by country  
 
A. All individuals 
Country λ (95% CI) r (95% CI) 
Ethiopia 0.028 (0.022, 0.036) 0.015 (0.007, 0.033) 
Ghana 0.240 (0.192, 0.299) 0.015 (0.009, 0.024) 
Mali 0.077 (0.064, 0.091) 0.017 (0.011, 0.027) 
Niger 0.110(0.093, 0.130) 0.009 (0.005, 0.018) 
Nigeria 0.052 (0.044, 0.062) 0.005 (0.000, 0.485) 
Senegal 0.434 (0.282, 0.670) 0.63 .033, 0.124) 
 
B. Excluding individuals with a history of recent meningococcal vaccination 
Country λ (95% CI) r (95% CI) 
Ethiopia 0.028 (0.022, 0.036) 0.015 (0.007, 0.333) 
Ghana 0.233 (0.183, 0.295) 0.015 (0.008, 0.025) 
Mali 0.075 (0.063, 0.090) 0.016 (0.010, 0.027) 
Niger 0.114 (0.095, 0.137) 0.010 (0.005, 0.020) 
Nigeria 0.050 (0.042, 0.060) 0.0002 (0, 1)  
Senegal 0.457 (0.160, 1.30) 0.109 (0.031, 0.380) 
 
 
